(Q45327793)

13 December 2017

Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. (English)

1 reference

13 December 2017

1 reference

1 reference

3

1 reference

13 December 2017

6

1 reference

13 December 2017

Cinzia Crivellaro

1

0 references

author name string

Mauro Signorelli

2

1 reference

13 December 2017

Elena De Ponti

4

1 reference

13 December 2017

Cecilia Pirovano

5

1 reference

13 December 2017

Federica Elisei

7

1 reference

13 December 2017

Luca Montanelli

8

1 reference

13 December 2017

Alessandro Buda

9

1 reference

13 December 2017

Cristina Messa

10

1 reference

13 December 2017

language of work or name

English

0 references

publication date

23 May 2013

1 reference

13 December 2017

1 reference

13 December 2017

130

1 reference

13 December 2017

2

1 reference

13 December 2017

306-311

1 reference

Global cancer statistics, 2002

13 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

The role of comprehensive surgical staging in patients with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Issues surrounding lymphadenectomy in the management of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Role of complete lymphadenectomy in endometrioid uterine cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

The outcomes of 27,063 women with unstaged endometrioid uterine cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Controversies in surgical staging of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Clinical value of FDG-PET for preoperative evaluation of endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

18F-FDG PET in the management of endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Endometrial cancer: magnetic resonance imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Computed tomography in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized tomography or magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Evaluation of endometrial carcinoma on magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Influence of histological features and treatment on the prognosis of patients with cervical cancer metastatic to pelvic lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Lymphvascular space involvement--a prognostic indicator in endometrial adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Prognostic significance of gross myometrial invasion with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Surgical stage I endometrial cancer: predictors of distant failure and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

Endometrial cancer and lymph node surgery: the spins continue--a case for reason

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.011

10.1016/J.YGYNO.2013.05.011

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference